



| 1994   | 1995   | 1996   | 1997   | 1998   | 1999   | 2000   | 2001   | 2002   | 2003   | 2004   | 2005   | 2006   | 2007   | 2008  | 2009  | 2010  | 2011  | © VALUE LINE PUB., INC. | 13-15 |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|-------|-------|-------|-------------------------|-------|
| 9.78   | 9.96   | 10.48  | 10.69  | 11.31  | 10.21  | 10.79  | 11.28  | 12.34  | 13.85  | 15.82  | 17.03  | 19.25  | 21.98  | 24.67 | 26.43 | 28.70 | 30.90 | Sales per sh            | 42.80 |
| 1.26   | 1.32   | 1.41   | 1.35   | 1.50   | 1.64   | 1.72   | 1.87   | 2.12   | 2.40   | 3.03   | 3.76   | 4.14   | 4.85   | 5.50  | 6.29  | 7.30  | 7.30  | "Cash Flow" per sh      | 9.05  |
| .89    | .89    | .91    | .83    | .86    | 1.14   | 1.23   | 1.38   | 1.68   | 1.94   | 2.45   | 3.03   | 3.29   | 3.84   | 4.44  | 4.79  | 5.50  | 6.20  | Earnings per sh A       | 7.80  |
| .29    | .31    | .33    | .35    | .37    | .39    | .41    | .42    | .43    | .45    | .47    | .50    | .54    | .58    | .62   | .66   | .70   | .74   | Div's Decl'd per sh B   | .85   |
| .33    | .35    | .37    | .29    | .43    | .26    | .19    | .26    | .40    | .70    | .71    | .93    | .68    | .51    | .51   | .50   | .60   | .75   | Cap'l Spending per sh   | .95   |
| 4.23   | 4.94   | 5.28   | 5.05   | 5.51   | 5.65   | 6.03   | 7.53   | 8.53   | 10.10  | 12.99  | 14.77  | 16.46  | 18.44  | 19.89 | 22.87 | 20.40 | 22.85 | Book Value per sh C     | 39.25 |
| 104.10 | 114.20 | 113.97 | 113.57 | 103.00 | 101.56 | 101.82 | 104.77 | 103.21 | 103.51 | 104.67 | 104.01 | 103.16 | 100.19 | 99.39 | 95.92 | 95.00 | 92.50 | Common Shs Outst'g D    | 90.00 |
| 14.5   | 16.3   | 17.6   | 19.0   | 22.2   | 22.2   | 18.4   | 18.9   | 16.4   | 17.6   | 21.9   | 22.0   | 22.3   | 21.7   | 20.5  | 15.3  | 10.2  | 10.2  | Avg Ann'l P/E Ratio     | 18.0  |
| .95    | 1.09   | 1.10   | 1.10   | 1.15   | 1.27   | 1.20   | .97    | .90    | 1.00   | 1.16   | 1.17   | 1.20   | 1.15   | 1.23  | 1.02  | 1.02  | 1.02  | Relative P/E Ratio      | 1.20  |
| 2.3%   | 2.1%   | 2.1%   | 2.2%   | 1.9%   | 1.5%   | 1.8%   | 1.6%   | 1.6%   | 1.3%   | .9%    | .7%    | .7%    | .7%    | .7%   | .8%   | .8%   | .8%   | Avg Ann'l Div'd Yield   | .6%   |

|  |  |  |  |  |        |        |        |        |        |        |        |        |        |        |       |       |                         |       |
|--|--|--|--|--|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|-------|-------------------------|-------|
| <b>CAPITAL STRUCTURE as of 3/31/10</b>                         |  |  |  |  | 1098.8 | 1181.3 | 1273.8 | 1433.1 | 1656.1 | 1771.3 | 1985.5 | 2202.0 | 2452.1 | 2534.9 | 2725  | 2860  | Sales (\$mill)          | 3850  |
| Total Debt \$149.8 mill. Due in 5 Yrs \$50.0 mill.             |  |  |  |  | 22.2%  | 22.6%  | 23.1%  | 23.2%  | 25.2%  | 28.4%  | 27.7%  | 28.9%  | 30.0%  | 32.6%  | 30.4% | 29.0% | Operating Margin        | 29.0% |
| LT Debt \$149.8 mill. LT Interest \$10.0 mill.                 |  |  |  |  | 49.6   | 53.2   | 42.3   | 44.7   | 54.7   | 63.8   | 74.9   | 80.0   | 90.9   | 93.5   | 95.0  | 100   | Depreciation (\$mill)   | 115   |
| (6% of Cap'l)  |  |  |  |  | 125.3  | 143.2  | 176.9  | 204.0  | 262.7  | 327.4  | 351.8  | 406.4  | 455.4  | 509.5  | 530   | 575   | Net Profit (\$mill)     | 700   |
| <b>Leases, Uncapitalized Annual Rentals \$22.4 mill.</b>       |  |  |  |  | 30.2%  | 30.1%  | 28.1%  | 27.5%  | 26.5%  | 26.0%  | 27.5%  | 29.6%  | 28.9%  | 29.4%  | 27.0% | 27.0% | Income Tax Rate         | 27.0% |
| <b>Pension Assets-12/09 \$239.1 mill. Oblig. \$348.6 mill.</b> |  |  |  |  | 11.4%  | 12.1%  | 13.9%  | 14.2%  | 15.9%  | 18.5%  | 17.7%  | 18.5%  | 18.6%  | 20.1%  | 19.4% | 20.1% | Net Profit Margin       | 19.0% |
| <b>Pfd Stock None</b>  |  |  |  |  | 302.1  | 412.9  | 441.1  | 453.2  | 663.7  | 623.5  | 838.0  | 960.3  | 1081.1 | 1210.1 | 1130  | 1240  | Working Cap'l (\$mill)  | 1390  |
| <b>Common Stock 95,097,102 shares</b>                          |  |  |  |  | 204.3  | 156.4  | 152.2  | 151.5  | 151.4  | .8     | 150.6  | 149.8  | 149.8  | 149.8  | 150   | 150   | Long-Term Debt (\$mill) | 150   |
| <b>MARKET CAP: \$7.9 billion (Large Cap)</b>                   |  |  |  |  | 613.9  | 788.7  | 880.4  | 1045.7 | 1360.1 | 1536.1 | 1698.0 | 1848.0 | 1977.2 | 2193.6 | 2215  | 2380  | Share Equity (\$mill)   | 3230  |
| <b>CURRENT POSITION</b>  |  |  |  |  | 16.5%  | 15.9%  | 17.7%  | 17.6%  | 17.8%  | 21.7%  | 19.5%  | 20.6%  | 21.7%  | 22.0%  | 22.5% | 22.5% | Return on Total Cap'l   | 19.0% |
|  |  |  |  |  | 20.4%  | 18.2%  | 20.1%  | 19.5%  | 19.3%  | 21.3%  | 20.7%  | 22.0%  | 23.0%  | 23.2%  | 24.0% | 24.0% | Return on Shr. Equity   | 20.0% |
|  |  |  |  |  | 13.6%  | 12.7%  | 15.0%  | 15.0%  | 15.7%  | 17.9%  | 17.4%  | 18.7%  | 19.9%  | 20.2%  | 21.0% | 21.0% | Retained to Com Eq      | 17.5% |
|  |  |  |  |  | 33%    | 30%    | 25%    | 23%    | 19%    | 16%    | 16%    | 15%    | 14%    | 13%    | 13%   | 12%   | All Div's to Net Prof   | 11%   |

**BUSINESS:** C.R. Bard, Inc. has four core segments: Vascular (27% of '09 sales): angioplasty & angiography catheters, stents, vasc. grafts & blood oxygenators. Urology (27%): Foley catheters, urine collection sys. & incontinence aids. Oncology (27%): specialty access catheters & ports, gastroenterological pdts. & bladder & prostate cancer tests. Surgical Specialties (15%): hernia repair pdts. & orthopedic & laparoscopic irrigation pdts. "Other" (4%): deemphasized pdts. Int'l, 30.6% of total, R&D, 7.1%. '09 depr. rate: 15.4%. Has 11,000 empls. Off./dir. own 3.4% of common; FMR, 9.6%; T.Rowe Price, 6.2%; BlackRock, 5.6% (3/10 Proxy). Chrmn. & CEO: Timothy M. Ring, Inc.: NJ. Addr.: 730 Central Ave, Murray Hill, NJ 07974. Tel.: 908-277-8000. Internet: www.crbard.com.

**C.R. Bard is building momentum.** The medical equipment company got off to a strong start in 2010. First-quarter revenues advanced 9% and share net grew 6%, year over year. Improved market conditions helped bolster results domestically, and international sales were up roughly 15% during the interim. In addition, we believe that Bard's well-diversified portfolio mix strengthened the quarterly performance. Looking forward, **The company ought to post solid top and bottom-line near-term results.** Its business development efforts and ongoing initiatives should help offset the pressures of a somewhat more competitive environment. Management has been focusing on technological improvements. As a result, it has increased research and development spending. Product innovation should be key to long-term gains. In the first quarter, eight product launches were well received. Also, BCR's ongoing stock-repurchase program should help boost per-share comparisons. In sum, we look for revenues to grow another 5%-10% this year. Moreover, profits should continue to grow at a 10%-15% annual clip in 2010 and 2011.

**Acquisitions ought to help, too.** In the beginning of the second quarter, Bard purchased FlowCardia for \$80 million. This addition should advance its lower-limb arterial business strategy. And in early May, Bard announced plans to acquire SenoRx, Inc. for \$11.00 a share, for net proceeds of \$200 million. SenoRx makes devices that help detect and treat breast cancer. The transaction, which is still subject to regulatory approval, ought to complement the Peripheral Vascular division. The company will probably eye additional asset purchases that will be accretive to its product pipeline. **This issue has some room to run.** As the baby-boomer generation ages, and relies more heavily on healthcare services, it will lift demand for Bard's products. Even though BCR is now ranked to only track the broader market averages, it offers worthwhile capital gains possibilities over the next 3 to 5 years. What's more, the company's sterling finances and perfect scores for Price Stability and Safety may appeal to conservative investors.

*Orly Seidman* May 28, 2010

|  |  |  |  |  |   |  |  |  |  |                                    |  |  |  |  |                                     |  |  |  |  |                                    |  |  |  |  |
|--|--|--|--|--|---|--|--|--|--|------------------------------------|--|--|--|--|-------------------------------------|--|--|--|--|------------------------------------|--|--|--|--|
| <b>(A)</b> Based on avg. shs. outstanding until '96, dil. thereafter. Excl. net n/r.: '94, d17c; '95, d12c; '96, d10c; '97, d20c; '98, \$1.40; '99, 1c; '00, d18c; '02, d21c; '03, d34c; '04, 37c; '05, 9c; '06, d74c; '08, d38c; '09, Q1, d7c; Q2, d12c. Incl. one-time gain from add'l month of acct'g. for fgn. operations: '98, 2c. Qtrly eggs. may not sum due to rounding. Next eggs. rpt. due late April. <b>(B)</b> Dividends hist. paid in early Feb., May, Aug., and Nov. ■ Div'd reinv. plan avail. <b>(C)</b> Incl. intang. In '09: \$913.8 mill., \$9.53/sh. <b>(D)</b> In mill., adj. for split. |  |  |  |  | <b>Company's Financial Strength</b> A++ |  |  |  |  | <b>Stock's Price Stability</b> 100 |  |  |  |  | <b>Price Growth Persistence</b> 100 |  |  |  |  | <b>Earnings Predictability</b> 100 |  |  |  |  |
|--|--|--|--|--|---|--|--|--|--|------------------------------------|--|--|--|--|-------------------------------------|--|--|--|--|------------------------------------|--|--|--|--|